カテゴリー： DelveInsight, MOA2018, 世界, 医療/バイオ

インターロイキン－2阻害剤のパイプライン・インサイト2018

◆英語タイトル：Interleukin-2 (IL-2) Inhibitors -Pipeline Insights, 2018
◆商品コード：DIMR2016404
◆発行会社（調査会社）：DelveInsight
◆発行日：2018年08月
◆ページ数：約60
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール（受注後3営業日）
◆調査対象地域：グローバル
◆産業分野：製薬
◆販売価格オプション（消費税別）
Single User（1名使用）USD1,250 ⇒換算￥137,500見積依頼/購入/質問フォーム
Site Price（同一国内共有可）USD2,500 ⇒換算￥275,000見積依頼/購入/質問フォーム
Enterprise Price（複数国内共有可）USD4,000 ⇒換算￥440,000見積依頼/購入/質問フォーム
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日～2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・郵送（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
本調査レポートでは、世界におけるインターロイキン－2阻害剤のパイプライン動向について調査・分析し、以下の構成でお届けいたします。

・インターロイキン－2阻害剤の概要
・インターロイキン－2阻害剤のパイプライン概要
・企業別開発中のインターロイキン－2阻害剤
・後期治験段階の薬剤(Filed & Phase III)：比較分析
・中期治験段階の薬剤(Phase II)：比較分析
・初期治験段階の薬剤(Phase I & IND Filed)：比較分析
・薬剤候補のプロファイル
・インターロイキン－2阻害剤の評価
　　- 単剤治療薬別評価
　　- 併用治療薬別評価
　　- 投与経路別評価
　　- 分子種類別評価
・開発が中止された薬剤リスト
・開発休止中の薬剤リスト
・インターロイキン－2阻害剤開発に取り組んでいる企業リスト
・図表一覧
【レポートの概要】

SUMMARY
DelveInsight’s, “Interleukin-2 (IL-2) Inhibitors-Pipeline Insights, 2018”, report provides in depth insights on the pipeline drugs and their development activities around the Interleukin-2 (IL-2) Inhibitors. The DelveInsight’s Report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Interleukin-2 (IL-2) Inhibitors. DelveInsight’s Report also assesses the Interleukin-2 (IL-2) Inhibitors therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration.

Please note: This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated indication.


Scope
• The report provides competitive pipeline landscape of Interleukin-2 (IL-2) Inhibitors
• The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
• Coverage of the Interleukin-2 (IL-2) Inhibitors pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
• The report reviews key players involved in the therapeutics development for Interleukin-2 (IL-2) Inhibitors and also provide company profiling
• The report also gives the information of dormant and discontinued pipeline projects
• Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
• Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type


【レポートの目次】

Table of Contents
• Interleukin-2 (IL-2) Inhibitors Overview
• Interleukin-2 (IL-2) Inhibitors Disease Associated
• Interleukin-2 (IL-2) Inhibitors Pipeline Therapeutics
• Interleukin-2 (IL-2) Inhibitors Therapeutics under Development by Companies
• Interleukin-2 (IL-2) Inhibitors Filed and Phase III Products
• Comparative Analysis
• Interleukin-2 (IL-2) Inhibitors Phase II Products
• Comparative Analysis
• Interleukin-2 (IL-2) Inhibitors Phase I and IND Filed Products
• Comparative Analysis
• Interleukin-2 (IL-2) Inhibitors Discovery and Pre-Clinical Stage Products
• Comparative Analysis
• Drug Candidate Profiles
• Interleukin-2 (IL-2) Inhibitors – Therapeutics Assessment
• Assessment by Monotherapy Products
• Assessment by Combination Products
• Assessment by Route of Administration
• Assessment by Molecule Type
• Interleukin-2 (IL-2) Inhibitors – Discontinued Products
• Interleukin-2 (IL-2) Inhibitors – Dormant Products
• Companies Involved in Therapeutics Development for Interleukin-2 (IL-2) Inhibitors
• Appendix
• Methodology
• Contact Us
• Disclaimer

List of Tables
• Number of Products under Development for Interleukin-2 (IL-2) Inhibitors by Therapy Area, 2018
• Number of Products under Development for Interleukin-2 (IL-2) Inhibitors, 2018
• Number of Products under Development by Companies
• Comparative Analysis by Filed and Phase III Products, 2018
• Comparative Analysis Phase II Products, 2018
• Comparative Analysis Phase I and IND Filed Products, 2018
• Comparative Analysis Discovery and Pre-Clinical Stage Products, 2018
• Drug Candidates Profiles
• Interleukin-2 (IL-2) Inhibitors Assessment by Monotherapy Products
• Interleukin-2 (IL-2) Inhibitors Assessment by Combination Products
• Interleukin-2 (IL-2) Inhibitors Assessment by Route of Administration
• Interleukin-2 (IL-2) Inhibitors Assessment by Stage and Route of Administration
• Interleukin-2 (IL-2) Inhibitors Assessment by Molecule Type
• Interleukin-2 (IL-2) Inhibitors Assessment by Stage and Molecule Type
• Interleukin-2 (IL-2) Inhibitors Therapeutics – Discontinued Products
• Interleukin-2 (IL-2) Inhibitors Therapeutics – Dormant Products
• Products under Development by Companies, 2018


List of Figures
• Number of Products under Development for Interleukin-2 (IL-2) Inhibitors by Therapy Area, 2018
• Number of Products under Development for Interleukin-2 (IL-2) Inhibitors, 2018
• Filed and Phase III Products, 2018
• Phase II Products, 2018
• Phase I and IND Filed Products, 2018
• Discovery and Pre-Clinical Stage Products, 2018
• Interleukin-2 (IL-2) Inhibitors Assessment by Monotherapy Products
• Interleukin-2 (IL-2) Inhibitors Assessment by Combination Products
• Interleukin-2 (IL-2) Inhibitors Assessment by Route of Administration
• Interleukin-2 (IL-2) Inhibitors Assessment by Stage and Route of Administration
• Interleukin-2 (IL-2) Inhibitors Assessment by Molecule Type
• Interleukin-2 (IL-2) Inhibitors Assessment by Stage and Molecule Type


【レポートのキーワード】

インターロイキン－2阻害剤、医薬品、製薬、研究開発、パイプライン、治療、治験

★調査レポート[インターロイキン－2阻害剤のパイプライン・インサイト2018] (コード：DIMR2016404)販売に関する免責事項を必ずご確認ください。
★調査レポート[インターロイキン－2阻害剤のパイプライン・インサイト2018]についてメールでお問い合わせ
◆関連市場調査レポート◆
  • インターロイキン-1阻害剤のパイプライン・インサイト2018
  • インターロイキン-12阻害剤のパイプライン・インサイト2018
  • インターロイキン-13阻害剤のパイプライン・インサイト2018
  • インターロイキン－15（IL-15）阻害剤のパイプライン・インサイト2018
  • インターロイキン－16（IL-16）阻害剤のパイプライン・インサイト2018
  • インターロイキン－17（IL-17）阻害剤のパイプライン・インサイト2018
  • インターロイキン－23阻害剤のパイプライン・インサイト2018
  • インターロイキン－4阻害剤のパイプライン・インサイト2018
  • インターロイキン－5阻害剤のパイプライン・インサイト2018
  • インターロイキン－8阻害剤のパイプライン・インサイト2018

    • ◆H&Iグローバルリサーチのお客様（例）◆